Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients.

Journal of the American Academy of Dermatology - 1 Sept 2015

Mochel Mark C, Hammond Marc R, Frederick Dennie T, Alora-Palli Maria B, Piris Adriano, Flaherty Keith T, Hoang Mai P

Abstract excerpt

BACKGROUND: There are limited descriptions of histopathology and immune profiles of new or changing melanocytic nevi in the setting of B-Raf proto-oncogene (BRAF) inhibitor therapy. OBJECTIVE: We sought to identify their distinctive features. METHODS: Clinical charts and histologic review, neuroblastoma RAS viral (v-ras) oncogene homolog genotyping, and immunohistochemistry for HMB-45, BRAFV600E, phosphorylated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy, Needle
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Nevus, Pigmented

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogenes

Share to Skin Neoplasms

Source

Identifiers

PMID: 26190239
DOI: 10.1016/j.jaad.2015.06.006

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients.PMID 26190239Read ↗

BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.Semantic proximity Read ↗

BRAF Mutations Are Common Somatic Events in Melanocytic Nevi11Tables 2 and 3 can be found at http://www.blackwellpublishing.com/products/journals/suppmat/jid/jid22225/jid22225sm.htmSemantic proximity Read ↗

New and evolving concepts of melanocytic nevi and melanocytomas.Semantic proximity Read ↗

T1799A BRAF mutations in conjunctival melanocytic lesions.Semantic proximity Read ↗

Decoding the Molecular Mechanisms of BRAF V600E-Induced Nevi Formation.Semantic proximity Read ↗

Genetics of melanocytic nevi.Semantic proximity Read ↗

BRAF somatic mutations in malignant melanoma and melanocytic naevi.Semantic proximity Read ↗

Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.Semantic proximity Read ↗

Nevi and Melanoma.Semantic proximity Read ↗

Kinase Fusions in Spitz Melanocytic Tumors: The Past, the Present, and the FutureSemantic proximity Read ↗

Mosaic BRAF Fusions Are a Recurrent Cause of Congenital Melanocytic Nevi Targetable by MAPK Pathway Inhibition.Semantic proximity Read ↗

High frequency of BRAF mutations in nevi.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.